Evoke Pharma (EVOK) Misses Q3 EPS by 95c

Evoke Pharma (NASDAQ: EVOK) reported Q3 EPS of ($0.94), $0.95 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $2.65 million versus the consensus estimate of $4.1 million.

For earnings history and earnings-related data on Evoke Pharma (EVOK) click here.

You May Also Be Interested In

• Anthropic Signs $35b Cloud Deal With Lambda In Texas: WSJ
• Lobe Sciences closes $2.16M private placement for S-100 drug program
• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short